This is a new adventure in which Morocco has embarked. That of producing cannabis-based treatments and medicines. To do this, and after the establishment of the legal framework, the training of managers is one of the significant steps for the launch of this process which will raise Morocco to the rank of countries which produce medical treatments based on cannabis.
The Moroccan Consultative Association for the Use of Cannabis (AMCUC) in partnership with a pharmaceutical laboratory, launched the third phase of the program ” Kif Takwine to train 20 doctors and pharmacists in the medicinal and therapeutic uses of cannabis.
“It is a training course organized in collaboration with professors and researchers in cannabis, Israelis in particular. It is a training that consists in knowing very well this medicinal plant, its constituents and its components, since each year we discover new components. But this year we will focus on the components already validated by researchers for 30 or 40 years, in particular the Israeli, Pr. Raphael Mechoulam, recognized as the father of cannabis science.“, says Pr. Redouane Rabii, President of the AMCUC.
In detail, Pr. Rabii explains to us that this training aims to know how these substances act, what are the side effects and the advantages for certain diseases.
” Once the mechanism is mastered, it’s like a prerequisite. And from there, we will move on to the indications validated by research in terms of its drugs, and how to handle them because they are very different from normal drugs. Monitoring is needed to adapt the dosage to each patient in the future“, explains the expert.
Physicians and pharmacists selected under the program “ Kif Takwine » already have basic training. » The training will therefore be much more interactive to answer all their questions and queries, in order to make things easier for them. This will make it possible to have a common language. And even in the future, if there are prescriptions for pathologies, we will know very well which indications are validated“, explains Pr. Rabii.
The aim is to enable its doctors and pharmacists to have in-depth knowledge of the subject, so that in one year, when setting up the production project for its cannabis-based medicines, and after carrying out the necessary research and validation of results, “ everyone speaks the same language“, entrusts us the president of the AMCUC, who specifies that the important thing for him, ” is to avoid having side effects for our patientss”.
” When you control something, you control both its effects and the genetic indications.“, he underlines.
This is therefore the first training course on the medicinal and therapeutic uses of cannabis in Morocco. In collaboration with researchers specializing in cannabis, the process had started well before the launch of the training, Prof. Rabii tells us, on how to make this project a success and give ideas on what is being done elsewhere in the countries that preceded us. and who have clearly clarified the operation and the prescription.
» There we begin to be more and more in-depth and ground-level with our colleagues. In the future, there will be more and more ad hoc training on specific pathologies, dissected for the benefit of people interested in this field.“, announces the president of the AMCUC.
The Association has previously signed several partnerships with national and international universities, laboratories, players in the medical industry sector, research centers and international organizations to draw up a training program covering all industrial fields related with cannabis, and particularly those aimed at the manufacture of drugs.
This training will also be an opportunity to visit one of the largest pharmaceutical laboratories in Morocco, in order to learn more about its experiences in the field.
Morocco adopted, almost a year ago, the law organizing the legal uses, for pharmaceutical, medicinal and industrial purposes of cannabis. To do so, the Kingdom has also created the National Cannabis Regulatory Agency (ANRC), responsible for issuing the necessary authorizations to pharmaceutical laboratories wishing to embark on this adventure.